Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ocugen Inc (NQ: OCGN )

1.140 -0.040 (-3.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,594,610
Open 1.190
Bid (Size) 1.130 (15)
Ask (Size) 1.150 (30)
Prev. Close 1.180
Today's Range 1.120 - 1.200
52wk Range 0.3450 - 2.105
Shares Outstanding 257,328,085
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
From Ocugen
Via GlobeNewswire
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
From Ocugen
Via GlobeNewswire

Performance

YTD
+73.36%
+73.36%
1 Month
-3.39%
-3.39%
3 Month
-28.75%
-28.75%
6 Month
+15.38%
+15.38%
1 Year
+165.12%
+165.12%

More News

Read More
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
Peering Into Ocugen's Recent Short Interest
Via Benzinga
Why Ocugen (OCGN) Stock Is Falling
Via Benzinga
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Ocugen (OCGN) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
InvestorNewsBreaks – Ocugen Inc. (NASDAQ: OCGN) Closes on $35M Public Offering
Via Investor Brand Network
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
Via The Motley Fool
3 Penny Stocks That Could Turn $10K Into $100K in 3 Years
Via InvestorPlace
7 A-Rated Penny Stocks to Beat June Gloom
Via InvestorPlace
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
From Ocugen
Via GlobeNewswire
3 Penny Stocks Set to Make New Millionaires in 2024
Via InvestorPlace
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
7 A-Rated Biotech Stocks Worth Betting on in June
Via InvestorPlace
OCGN DEADLINE TODAY: TOP RANKED ROSEN LAW FIRM Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm – OCGN
From The Rosen Law Firm PA
Via GlobeNewswire
OCGN DEADLINE TODAY: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm – OCGN
From The Rosen Law Firm, P.A.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.